Cargando…

Independent test of a model to predict severe acute esophagitis

PURPOSE: Treatment planning factors are known to affect the risk of severe acute esophagitis during thoracic radiation therapy. We tested a previously published model to predict the risk of severe acute esophagitis on an independent data set. METHODS AND MATERIALS: The data set consists of data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ellen X., Robinson, Clifford G., Molotievschi, Alerson, Bradley, Jeffrey D., Deasy, Joseph O., Oh, Jung Hun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514225/
https://www.ncbi.nlm.nih.gov/pubmed/28740914
http://dx.doi.org/10.1016/j.adro.2016.11.003
Descripción
Sumario:PURPOSE: Treatment planning factors are known to affect the risk of severe acute esophagitis during thoracic radiation therapy. We tested a previously published model to predict the risk of severe acute esophagitis on an independent data set. METHODS AND MATERIALS: The data set consists of data from patients who had recoverable treatment plans and received definitive radiation therapy for non–small cell carcinoma of the lung at a single institution between November 2004 and January 2010. Complete esophagus dose-volume and available clinical information was extracted using our in-house software. The previously published model was a logistic function with a combination of mean esophageal dose and use of concurrent chemotherapy. In addition to testing the previous model, we used a novel, machine learning-based method to build a maximally predictive model. RESULTS: Ninety-four patients (81.7%) developed Common Terminology Criteria for Adverse Events, Version 4, Grade 2 or more severe esophagitis (Grade 2: n = 79 and Grade 3: n = 15). Univariate analysis revealed that the most statistically significant dose-volume parameters included percentage of esophagus volume receiving ≥40 to 60 Gy, minimum dose to the highest 20% of esophagus volume (D20) to D35, and mean dose. Other significant predictors included concurrent chemotherapy and patient age. The previously published model predicted risk effectively with a Spearman's rank correlation coefficient (r(s)) of 0.43 (P < .001) with good calibration (Hosmer-Lemeshow goodness of fit: P = .537). A new model that was built from the current data set found the same variables, yielding an r(s) of 0.43 (P < .001) with a logistic function of 0.0853 × mean esophageal dose [Gy] + 1.49 × concurrent chemotherapy [1/0] − 1.75 and Hosmer-Lemeshow P = .659. A novel preconditioned least absolute shrinkage and selection operator method yielded an average r(s) of 0.38 on 100 bootstrapped data sets. CONCLUSIONS: The previously published model was validated on an independent data set and determined to be nearly as predictive as the best possible two-parameter logistic model even though it overpredicted risk systematically. A novel, machine learning-based model using a bootstrapping approach showed reasonable predictive power.